C - reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis
Keywords:
C-reactive protein, CRP, inflammation, tissue death, physiological processesAbstract
C-reactive protein (CRP), an acute phase protein belonging to pentraxin family of proteins, increases 1000-fold or more in concentration in blood during the occurrence of an injury, inflammation or tissue death. CRP is known to be involved in conjugation of pathogens to induce their destruction by complement system and is also studied as a marker of inflammation, disease activity and a diagnostic adjunct. This review focuses on the diagnostic significance of CRP in various disease conditions as well as the established and controversial evidence on its physiological role.
References
Pepys MG and Hirschfield GM. C-reactive protein: a critical update. J Clin Invest2003;111(12).
Black S, Kushner I, Samols D. C-reactive protein. J BiolChem2004;279:48487-48490.
Ying SC, Marchalonis JJ, Gewurz AT, Siegel JN, Jiang H, Gewurz BE, et al.Reactivity of anti-human C-reactive protein (CRP)and serum amyloid P component (SAP) monoclonal antibodies with limulin and pentraxins of other species. Immunology 1992;76(2):324-330.
Pepys MB andBaltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins(pentaxins) and serum amyloid A protein. AdvImmunol1983;34:141-212.
Tillett WS and Francis T Jr. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-571.
Macleod C and Avery O. The occurrence during acute infections of a protein not normally present in the blood. II. Isolation and properties of the reactive protein. J Exp Med 1941;73:183-190.
McCarty M. The occurrence during acute infections of a protein not normally present in the blood. IV. Crystallization of the C-reactive protein. J Exp Med 1947;85:491-498.
Volanakis JE and Kaplan MH. Specifity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. ProcSocExpBiol Med 1971;136:612-614.
Clyne B, OlshakerJS.The C-reactive protein. J Emerg Med 1999;17(6):1019-1025.
Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44(1):6-11.
Kuta AE and Baum LL. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. JExpMed 1986;164:321-326.
Gould JM and Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun 2001;69(3):1747-1754.
Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, Fricke L, et al. The kidney as a second site of human C-reactive protein formation in vivo. Euro J Immunol 2003;33:152-161.
Yeh ETH. A new perspective on the biology of C-reactive protein. Circul Res 2005;97:609.
CalabróP,Willerson JT, Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930.
Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells. Potential for paracrine/autocrine effects. Am J Pathol2005;166(4):1265-1271.
Verma S and Yeh ETH. C-reactive protein and atherothrombosis—Beyond a biomarker:an actual partaker of lesion formation.Am J PhysiolRegulIntegr Comp Physiol 2003; 285:R1253–R1256.
Barna BP, James K, Deodhar SD. Activation of human monocyte tumoricidal activity by C-reactive protein. Cancer Res 1987;47(15):3959-3963.
Fiedel BA, Ku CS, Izzi JM, GewurzH.Selective inhibition of platelet activation by the amyloid P-component of serum. J Immunol 1983;131(3):1416-1419.
Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology and host defense function. ClinChem Lab Med. 1999;37(3):265-270.
Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol 1996;156(12):4815-4820.
J E Volanakis. Human C-reactive protein: expression, structure, and function. MolImmunol 2001.
Smitha CN, Soni S, Basu SK. Role of C-reactive protein and periodontal disease in systemic health: A review.JAdv Dent Res 2011;2(1):1-5.
Shephard EG, Anderson R, Rosen O, Myer MS, Fridkin M, Strachan AF, etal.Peptides generated from C-reactive protein by a neutrophil membrane protease. Amino acid sequence and effects of peptides on neutrophil oxidative metabolism and chemotaxis. J Immunol 1990;145(5):1469-1476.
Zouki C, Beauchamp M, Baron C, FilepJG.Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997;100(3):522-529.
Zouki C, Haas B, Chan JS, Potempa LA, FilepJG.Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol 2001;167(9):5355-5361.
Blake GJ and Ridker PM. C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? Am J Physiol Renal Physiol 2003;285.
Deban L, Bottazzi B, Garlanda C, de la Torre YM, Mantovani A. Pentraxins: multifunctional protiens at the interface of innate immunity and inflammation. Biofactors 2009;35(2):138-145.
Hage FG and Szalai AJ. The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk. CurrAtheroscler Reps 2009;11(2):124-130.
Woo P, Korenberg JR, Whitehead AS. Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J BiolChem 1985;260:13384-13388.
Lei KJ, Liu T, Zon G, Soravia E, Liu TY, Goldman ND. Genomic DNA sequence for human C-reactive protein. J BiolChem 1985;260:13377-13383.
Goldman ND, Liu T, Lei KJ. Structural analysis of the locus containing the human C-reactive protein gene and its related pseudogene. J BiolChem1987;262:7001-7005.
Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld, Williams A, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005;83(6):440-447.
Sölter J, UhlenbruckG.The biological importance of C-reactive proteins in non-specific defense mechanisms. ImmunInfekt 1982;10(4):130-135.
Du Clos TW. C-reactive protein reacts with the U1 small nuclear ribo-nucleoprotein. J. Immunol 1989;143:2553-2559.
Gershov D, Kim S, Brot N, Elkon K.B. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med 2000;192:1353-1363.
Black S, Agrawal A, Samols D. The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct. MolImmunol 2003;39(16):1045-1054.
De Rosa S, Cirillo P, Pacileo M, Di Palma V, Paglia A, ChiarielloM.Leptin stimulated C-reactive protein production by human coronary artery endothelial cells. J Vasc Res 2009;46(6):609-617.Epub 2009 Jun 30.
Agrawal A, Simpson MJ, Black S, Carey MP, Samols D.C-reactive protein mutant that does not bind to phosphocholine and pneumococcal C-polysaccharide. J Immunol 2002;169(6):3217-3222.
Wang HW, Wu Y, Chen Y, Sui SF. Polymorphism of structural forms of C-reactive protein. Int J Mol Med 2002;9(6):665-671.
Gotschlich EC and Edelman GM. C-reactive protein:a molecule composed of subunits. ProcNatlAcadSci USA 1965;54:558-562.
Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA. C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis. 2006;47(2):212-222.
HabersbergerJ, Eisenhardt SU, KarlheinzP. C-reactive protein measurement and cardiovascular disease. The Lancet 2010;375(9720):1078.
Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009;105(2):128-137.
Potempa LA, Maldonado BA, Laurent P, Zemel ES, Gewurz H. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. MolImmunol 1983;20(11):1165-1175.
Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol 1998;30(12):1415-1426.
McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908-2912.
Ji SR, Wu Y, Potempa LA, Liang YH, Zhao J. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. ArteriosclerThrombVascBiol 2006;26(4):935-941.
Boncler M, Luzak B, Watala C. Role of C-reactive protein in artherogensis. PostepyHig Med Dosw 2006; 60:538-546.
Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM.C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999;189(3):599-604.
Paul A1, Yeh ET, Chan L. A proatherogenic role for C-reactive protein in vivo. CurrOpinLipidol 2005; 16(5):512-517.
Potempa LA, Siegel JN, GewurzH.Binding reactivity of C-reactive protein for polycations. II. Modulatory effects of calcium and phosphocholine. J Immunol 1981;127(4):1509-1514.
Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al.Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke : A statement for healthcare professionals from the CRP pooling project members. Stroke 2005, 36:1316-1329.
Verma S, Wang C-H, Li S-H, Dumont AS, Fedak PWM, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
Ballou SP, LozanskiG.Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4(5):361-368.
Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. ArteriosclerThrombVasc Biol. 2000;20(9):2094-2099.
Peisajovich A, Marnell L, Mold C and DuClos TW. C-reactive protein at the interface between innate immunity and inflammation. Expert Rev ClinImmunol 2008;4(3):379-390.
Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Science 2003; 73(10):1245-1252.
Lakka HM, Lakka TA, Rankinen T et al. The TNF-α G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study. Vascular Pharmacology 2006;44(5): 377-383.
Nielsen FR, MøllerBek K, Rasmussen PE, Qvist I, Tobiassen M. CRP does not cross the placental barrier, and may therefore be useful in diagnosing infections in newborns. Biochem 2007; 40(5-6): 330-335.
Malek A, Bersinger NA, Di Santo S, Mueller MD, Sager R, Schneider H, et al. C-reactive protein production in term human placental tissue. Placenta2006; 27(6-7):619-625.
Coventry BJ, Ashdown ML, Quinn MA, MarkovicSN,Yatomi-Clarke SL and Robins AP. CRP identifieshomeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Trans Med 2009;7:102.
Groblewska M, Mroczko B, Wereszczyńska-Siemiatkowska U, Kedra B, Lukaszewicz M, BaniukiewiczA, et al. Serum interleukin 6 (IL-6) and C-reactive protein(CRP) levels in colorectal adenoma and cancer patients. ClinChem Lab Med 2008;46(10):1423-1428.
Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie2008; 31(12):665-670.
Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. CurrOncol Rep 2002; 4(3):250-255.
Shaw AC. Serum C-reactive protein and neopterin concentrations in patients with viral or bacterial infection. J ClinPathol. 1991;44(7):596-599.
Joo K, Park W, Lim MJ, Kwon SR, Yoon J. Serum procalcitonin for differentiating bacterial infection from disease flares in patients with autoimmune diseases. J Korean Med Sci. 2011;26(9):1147-1151.
Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med. 2009;24(4):337-342.
Karoui S, Ouerdiane S, Serghini M, Jomni T, Kallel L, Fekih M, et al. Correlation between levels of C-reactive protein and clinical activity in Crohn’s disease. Dig Liver Dis 2007;39(11):1006-1010.
Hajati AK, Alstergren P, Näsström K, Bratt J, Kopp S. Endogenous glutamate in association with inflammatory and hormonal factors modulates bone tissue resorption of the temporo-mandibular joint in patients with early rheumatoid arthritis. J Oral MaxillofacSurg2009;67(9):1895-1903.
Shah T, Casas JP, CooperJA, Tzoulaki I, Sofat R, McCormack V, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int. J. Epidemiol 2009; 38 (1):217-231.
Sajadieh, Nielsen OW, Rasmussen V, Ole Hein H, Hansen JF. Increased ventricular ectopic activity in relation to C-reactive protein, and NT-pro-brain natriuretic peptide in subjects with no apparent heart disease. Pacing ClinElectrophysiol 2006;29(11):1188-1194.
Schell-inderstP,SchwaezerR,Gphler A, Grandi N, GrabeinK,Stollenwerk B, et al. Prognostic value, clinical effectiveness and cost-effectiveness of highsensitivity C-reactive protein as a marker in primary prevention of major cardiac events. 2009;5:1861-8863.
Badran HM, Elnoamany MF, Khalil TS, Eldin MM. Age-related alteration of risk profile, inflammatory response, and angiographic findings in patients with acute coronary syndrome. Clin Med Cardiol 2009;18(3):15-28.
Williams ES, Shah SJ, Ali S, Na BY, Schiller NB, Whooley MA. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail 2008;10(1):63-69.
Nolan RP, Reid GJ, Seidelin PH, Lau HK. C-reactive protein modulates vagal heart rate control in patients with coronary artery disease. ClinSci (Lond) 2007;112(8):449-456.
Wilson PW, Pencina M, Jacques P, Selhub J, D’Agostino R Sr, O’Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. CircCardiovascQual Outcomes 2008;1(2):92-97.
Perry TE, Muehlschlegel JD, Liu KY, Fox AA, Collard CD, Body SC, Shernan SK; CABG Genomics Investigators. Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting. Anesthesiology 2010;112(3):607-613.
Miller RG, Costacou T, Orchard TJ. Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. DiabVasc Dis Res 2010;7(1):47-55.
Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. CurrVascPharmacol 2010;6(4):258-270.
Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002;105(17):2019-2023.
Xu T, Ju Z, Tong W, Hu W, Liu Y, Zhao L, Zhang Y. Relationship of C-reactive protein with hypertension and interactions between increased C-reactive protein and other risk factors on hypertension in Mongolian people, China. Circ J. 2008;72(8):1324-1328.
Magen E, Mishal J, Paskin J, Glick Z, Yosefy C, Kidon M, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J ClinHypertens2008 ;10(9):677-683.
Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. C-reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. HypertensRes.2007 ;30(12):1177-1185.
Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I, Stefanadis C, Kallikazaros I. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol. 2005 ;96(2):252-256.
Cottone S, Mulè G, Nardi E, Vadalà A, Guarneri M, Briolotta C, Arsena R, Palermo A, Riccobene R, Cerasola G. Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens. 2006;19(3):313-318.
Lee YS, Ryu SY, Park J, Kang MG, Kim KS. [The association of high sensitivity C-reactive protein (hsCRP) with hypertension in some rural residents]. J Prev Med Public Health. 2005;38(3):325-329.
Kaplan RC, McGinn AP, Baird AE, Hendrix SL, Kooperberg C, Lynch J, et al. Inflammation and hemostat for predicting stroke in postmenopausal women: the Women’s Health Initiative Observational Study. J Stroke CerebrovascDis2008;17(6):344-355.
Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the ‘Bergen stroke study’. BMC Neurol2009 ;289-18.
Everett BM, Kurth T, Buring JE, Ridker PM. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am CollCardiol 2006;48(11):2235-2242.
Elkind MS, Luna JM, Moon YP, Liu KM, Spitalnik SL, Paik MC, Sacco RL. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology 2009;73(16):1300-1307.
Elkind MS, Leon V, Moon YP, Paik MC, Sacco RL. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke 2009;40(10):3233-3237.
Kosaku Komiya, Hiroshi Ishii, Shinji Teramoto, Osamu Takahashi, NobuokiEshima, Ou Yamaguchi, Noriyuki Ebi, Junji Murakami, Hidehiko Yamamoto and Jun-ichiKadota. Diagnostic utility of C-reactive Protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study. Respiratory Research 2011;12:83.
Urboniene D, Sakalauskas R, Sitkauskiene B. C-reactive protein levels in patients with chronic obstructive pulmonary disease and asthma. Medicina (Kaunas) 2008;44(11):833-840.
Garcia-Rio F, Miravitlles M, Soriano JB, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J; EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010;11:63.
Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 2010;25(10):1487-1491.
Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokersThorax2006;61(1):23-28.
Pandolfi A. C-reactive protein: A potential new molecular link between inflammation,thrombosis and vascular cell proliferation. Cardiovascular Research 2005;3-4.
Shi B, Ni Z, Cai H, Zhang M, Mou S, Wang Q, Cao L, Yu Z, Yan Y, Qian J.High-sensitivity C-reactive protein: an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis.JBiomed Biotechnol 2010:373426.
Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United StatesPLoS One 2011;6(2):e16103.
Nash DT. Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. J Natl Med Assoc2005;97(12):1600-1607.
Lewis TT, Aiello AE, PhD, Sue Leurgans, PhD, Jeremiah Kelly, MD, and Lisa L. Barnes, PhD. Self-reported Experiences of Everyday Discrimination are associated with Elevated C-Reactive Protein levels in older African-American Adults. Brain BehavImmun 2010; 24(3): 438-443.
Lee S, Choe J-W, Kim H-K and Sung J. High-Sensitivity C-Reactive Protein and Cancer, J. Epidemiology 2011;21(3):161-168.
Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer 2006;94(11):1568-1571.
Kruse AL, Luebbers HT, Grätz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol 2010;2:21.
Shiu YC, Lin JK, Huang CJ, Jiang JK, Wang LW, Huang HC, et al. Is C-reactive protein a prognostic factor of colorectal cancer? Dis Colon Rectum. 2008;51(4):443-449.
Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA.C-reactive protein and colorectal cancer risk: a systematic review of prospective studies.Int J Cancer 2008;123(5):1133-1140.
Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010;10:203.
Ortega-Deballon P, Radais F, Facy O, d’Athis P, Masson D, Charles PE, et al. C-reactive protein is an early predictor of septic complications after elective colorectal surgery. World J Surg 2010;34(4):808-814.
Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 2009;11(2):R22.
Arias JF, Nishihara R, Bala M, Ikuta K. High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses. Retrovirology 2010;7:15.
Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS 2007;21(7):479-491.
Boger MS1, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study.JAcquir Immune DeficSyndr. 2009 Dec 1;52(4):480-487.
Paran Y, Yablecovitch D, Choshen G, Zeitlin I, Rogowski O, Ben-Ami R, et al. C-reactive protein velocity to distinguish febrile bacterial infections from non-bacterial febrile illnesses in the emergency department. Crit Care. 2009;13(2):R50.
Outinen TK, Mäkelä SM, Ala-Houhala IO, Huhtala HS, Hurme M, Paakkala AS, et al. The severity of Puumalahanta virus induced nephropathiaepidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. BMC Infect Dis. 2010;10:132.
Zimmerman O, Rogowski O, Aviram G, Mizrahi M, Zeltser D, Justo D, et al. C-reactive protein serum levels as an early predictor of outcome in patients with pandemic H1N1 influenza A virus infection. BMC Infect Dis. 2010;10:288.
Zhang J, She D, Feng D, Jia Y, Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infect Dis 2011;11:53.
Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009;48(1):78-82.
Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes.Br Med J 1997;1(6055):195-197.
Holmes MV, Jiang B, McNeill K, Wong M, Oakley SP, Kirkham B, et al. Paradoxicalassociation of C-reactive protein with endothelial function in rheumatoid arthritis.PLoS One2010;5(4):e10242.
Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68(6):954-960.
Sidoroff M, Karikoski R, Raivio T, Savilahti E, Kolho KL. High-sensitivity C-reactive protein in paediatric inflammatory bowel disease.World J Gastroenterol 2010;16(23):2901-2906.
Kao AH, Wasko MC, Krishnaswami S, Wagner J, Edmundowicz D, Shaw P, et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis.Am J Cardiol. 2008 Sep 15;102(6):755-60.
Peters JH, Greasby T, Lane N, Woolf A. Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease. Biomarkers 2009;14(4):250-257.
Huffman FG, Gomez GP, Zarini GG. Metabolic syndrome and high-sensitivity C-reactive protein in Cubans. Ethn Dis 2009;19(2):115-120.
Ford ES, Ajani UA, Mokdad AH. National Health and Nutrition Examination. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth.Diabetes Care2005;28(4):878-881.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107(3):391-397.
Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology 2009;9:16.
Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalentdementia in the oldest-old. Alzheimers Dement. 2009;5(4):318-323.
Roberts RO, Geda YE, Knopman DS, Boeve BF, Christianson TJ, Pankratz VS, et al. Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement 2009;5(5):398-405.
Devaraj S, Siegel D, Jialal I. Statin therapy in metabolic syndrome and hypertension post-JUPITER: What is the value of CRP? CurrAtheroscler Rep 2011;13(1):31-42.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M, Koenig W.C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998.Arch Intern Med 2003;163(1):93-99.
Lee HM, Lopez VA, Le TY, Wong ND. Association of C-reactive protein withreduced forced vital capacity in anonsmoking U.S. population withmetabolic syndrome and diabetes. Diabetes Care2008;31:2000-2002.
Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of serum C-reactive protein level with sex-specific type 2 diabetes. J ClinEndocrinolMetab2009;94(6):2099-2105.
Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S, et al. High-sensitivity C-reactive protein and gamma-glutamyltransferase levels are synergistically associated with metabolic syndrome in community-dwelling persons. CardiovascDiabetol 2010;9:87.
Panaszek B, Liebhart E, Liebhart J, Pawłowicz R, Fal AM. Serum concentration of C-reactive protein is not a good marker of bronchial hyperresponsiveness. Arch ImmunolTherExp (Warsz) 2007;55(5):341-345.
Olafsdottir IS, Gislason T, Thjodleifsson B, Olafsson I, Gislason D, Jögi R, et al. C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax 2005;60(6):451-454.
Melbye H, Hvidsten D, Holm A, Nordbo SA, Brox J. The course of C-reactive protein response in untreated upper respiratory tract infection. Br J Gen Pract 2004; 54(506): 653–658.
Soriano S, González L, Martín-Malo A, Rodríguez M, Aljama P. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. ClinNephrol 2007;67(6):352-357.
Abraham G, Sundaram V, Sundaram V, Mathew M, Leslie N, Sathish V. C-Reactive protein, a valuable predictive marker in chronic kidney disease. Saudi J Kidney Dis Transpl 2009;20(5):811-815.
Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003;42(1):44-52.
Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005;68(2):766-772.
Golbasi Z, Ucar O, Keles T, Sahin A, Caglic K, Camsari A, Diker E, Aydogdu S. Increased levels of high sensitive C-reactive protein in patients withchronic rheumatic valve disease: evidence of ongoing inflammation.Eur J Heart Failure2002;4:593-595.
Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 2008;65(6):776-785.
